Where does Cellectis rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cellectis ranks #4,109 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cellectis hold?

Cellectis holds 87 US utility patents granted between 2015 and 2025, spanning 17 technology areas.

What is Cellectis's Innovation Score?

Cellectis has an Innovation Score of 43.4 out of 100 (top 28% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Cellectis's patent grant rate increasing or decreasing?

Cellectis's recent grant velocity is +73% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Cellectis's patents?

Cellectis's patents average 15.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cellectis patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cellectis

Q: What technology areas does Cellectis focus on?

Cellectis's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 82 patents. Grants appear in 17 CPC subclasses total.

USPTO PatentsView assignee record - 87 granted patents across 17 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cellectis ranks #4,109 of 49,997 tracked US assignees by granted-patent volume, with 87 patents across 17 technology areas.

#4,109
of 49,997 US assignees by volume: Top 28%
by Innovation Score (43.4/100): 15.6
avg claims per patent: +73%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4109 · Foreign Corporation #4,109 · 87 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 87 grants
TOP-DECILE #4,109/49,997
PHOTO-FINISH Beijing Tusen Zhitu…
CPC-FOCUS C12N · 17 areas
INNOV-PAR 43.4/100
CLAIMS-RICH 15.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +73% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Beijing Tusen Zhitu Technology Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Cellectis · this assignee

43
Chdi Foundation · near

43
Delta Kogyo · near

43
Nihon Plast · near

43
Tango Networks · near

43
3D Lighting… · lowest

7

What this shows Cellectis's Innovation Score is 43.4/100 (top 28% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Cellectis's grants concentrate

Cellectis is a focused PatentsView assignee: 17 CPC subclasses with 94.3% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2019 (17 grants) versus a trough of 1 in 2015. By volume, Cellectis sits between Belimo Holding AG and D2L Corporation.

Cellectis's three-year grant acceleration

From 2019–2021 to 2022–2024, Cellectis moved from 43 to 26 grants (0.60x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Belimo Holding

87
BIC Violex Single…

87
Beijing Tusen Zhi…

87
Board of Trustees…

87
Chanel Parfums Be…

87
Compagnie Plastic…

87
Cognitive Systems

87
D2L

87
Cellectis ◀

87

What this shows Cellectis holds 87 patents at rank #4,109, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cellectis

By rank, the assignees closest to #4,109 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Cellectis's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Cellectis, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (43 here).

Tango Networks, Inc. 43 Nihon Plast Co., Ltd. 43 Chdi Foundation, Inc. 43 Delta Kogyo Co., Ltd. 43

Similar claim depth

Nearest assignees by average claims per patent (15.6 here).

Bard Peripheral Vascular, Inc. 15.6 avg VKR Holding A/S 15.6 avg Shpp Global Technologies B.V. 15.6 avg Toshiba Memory Corporation 15.6 avg

Cellectis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 28% higher than 72% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Cellectis patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	1.1%
2016	3	3.4%
2017	1	1.1%
2018	8	9.2%
2019	17	19.5%
2020	16	18.4%
2021	10	11.5%
2022	10	11.5%
2023	7	8.0%
2024	9	10.3%
2025partial year	5	5.7%

Which technologies does Cellectis patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 82

C07K - Peptides 63

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 63

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 54

C12Y - Enzymes 15

Y02A - Technologies FOR Adaptation TO Climate Change 4

A01H - NEW Plants OR ; NON-TRANSGENIC; Processes FOR Obtaining THEM; Plant Reproduction BY Tissue Culture Techniques 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 3

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 2

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Y02E - Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution 1

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 1

C08B - POLYSACCHARIDES; Derivatives Thereof 1

Top 15 of 17 technology areas

Where it ranks

Overall rank by patents

#4,109

of 49,997 tracked assignees

Innovation Score

43.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Cellectis's patent record in context - here's where to go next.

Cellectis's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 94.3% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #4,109 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cellectis against Belimo Holding AG, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 43.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.